Submitted by Anonymous (not verified) on 19 January 2026 - 14:55
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 31, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 31, Status: Authorised